The Boston Simplus Multi-Action Solution is used to provide supportive care for wearers of Rigid Gas Permeable (RGP) contact lenses, and may assist with managing factors that can affect lens performance and comfort. The solution is commonly used to support the multi-action management of RGP lens hygiene, including cleaning, disinfection, and conditioning. This integrated approach is intended to help manage recurring symptomatic patterns associated with lens wear.

Prophylactic Management and Comfort

This domain covers the solution's function in routine lens disinfection, used to control the risk of microbial contamination that generally arises during handling and storage. This generally provides a non-acute form of support that is designed to support hygiene by assisting in the management of potential microbial contaminants from the lens surface prior to wear. This routine care may assist with maintaining stability because the effects of daily debris and microbial exposure may necessitate supportive lens hygiene.

The solution may assist with addressing the symptoms of reduced or hazy vision caused by deposit accumulation and supports the lens's surface wettability, which helps ease the mechanical friction and dryness. This combination of effects may help improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for RGP Lens Discomfort	Symptom Type	Supportive Benefit
Physical Discomfort	Assists with easing irritation and foreign body sensation.
Reduced Clarity	Helps manage blurring caused by surface deposits.
Contamination Risk	Supports routine, prophylactic microbial control.

Regulatory References

1. official FDA documentation on contact lens care products

Who Can and Cannot Use Boston Simplus Multi-Action Solution?

The official eligibility profile for this Over-the-Counter (OTC) solution is strictly defined by regulatory documentation, focusing on lens type and ingredient sensitivity.

Populations for Whom Use is Defined

Eligibility Category	Official Regulatory Status
Populations Allowed	Wearers of Rigid Gas Permeable (RGP) contact lenses (fluoro silicone acrylate and silicone acrylate materials).
Contraindicated Populations	Individuals with a known allergy to any ingredient in the product.
	Wearers of Soft (Hydrophilic) Contact Lenses (due to device incompatibility).

Systemic and Age-Related Eligibility

The regulatory labeling provides no documented restrictions regarding several population categories typical for systemic medicines:

• Age-related Eligibility: No specific age-based restrictions are documented for use in pediatric, adolescent, or older adult populations.
• Pregnancy and Lactation: The official labeling is silent on restrictions or recommendations for use during pregnancy or breastfeeding.
• Organ Function/Comorbidities: The labeling does not document eligibility limitations based on systemic conditions such as hepatic or renal impairment.

Regulatory Context

Official Eligibility Statements:

• Use is contraindicated if the individual is allergic to any ingredient in the solution.
• The product is Not For Use With Soft (Hydrophilic) Contact Lenses.

The eligibility status is therefore determined solely by the type of contact lens worn and the presence of ingredient hypersensitivity, as defined by the FDA-cleared labeling.

The official regulatory profile for Boston Simplus Multi-Action Solution is uniquely defined by its classification as a non-systemic ophthalmic biocide. As a result, its labeling documentation, derived from government health authorities, does not contain the typical pharmacokinetic interaction data (such as those mediated by CYP enzymes or drug transporters) that are associated with systemically absorbed oral or injectable medicines. This regulatory basis means the official interaction structure is characterized by the absence of conventional systemic drug-drug interactions.

Interaction-Related Constraints

The active biocide component, Chlorhexidine, has a documented substance-specific interaction pattern. Specifically, official monographs classify a serious interaction risk with certain biological materials, such as allogeneic cultured keratinocytes and dermal fibroblasts, which are found in some advanced wound care products. This imposes a formal restriction on co-exposure with this material.

No specific metabolic interactions, exposure modifications ( AUC/ C max changes), or timing-separation rules from other medicinal products are documented in official regulatory text for this solution. The most critical restriction documented in the labeling is the formal contraindication for any individual with a known allergy or hypersensitivity to any of the solution’s components, including Chlorhexidine or Polyaminopropyl Biguanide.

Mechanistic Action on the Lens and Ocular Interface

This multi-domain solution acts via three distinct physical and chemical mechanisms. Surface-active agents within the formula interact with the lens surface matrix, decreasing interfacial tension to lift, solubilize, and suspend organic debris and denatured protein deposits. The result of this detergent action is enhanced optical transparency of the lens surface.

Simultaneously, two different cationic biocides engage the microbial cell membranes of potential contaminants. This dual-action interaction chemically disrupts membrane integrity and permeability, which initiates a rapid destruction of microbial cell viability, thereby achieving comprehensive microbial load reduction.

Furthermore, conditioning polymers physically adsorb to the lens material, establishing a stable, viscoelastic hydrophilic film. This boundary layer increases the lens's lubricity and moisture retention, consequently reducing the coefficient of friction and limiting tissue interaction at the lens-ocular interface.

How Boston Simplus Multi-Action Solution Is Used

The usage of the Boston Simplus Multi-Action Solution is defined by a precise, daily, two-phase standard protocol for the care of Rigid Gas Permeable (RGP) contact lenses. The solution is intended exclusively for Topical/Ex Vivo Application to the surface of the lens device, not directly to the eye as a systemic treatment.

Dosing and Administration Constraints

The required usage protocol establishes specific numerical parameters for the cleaning phase. The process requires applying approximately four drops of the solution to the lens surface, followed by a mandatory manual rubbing period of 20 seconds for each side of the lens, and then rinsing for approximately 5 seconds with a steady stream of solution. This regimen is designated for daily use upon lens removal.

After the mechanical cleaning, the lenses must be placed in a case and immersed in fresh solution for a minimum duration of four hours for chemical disinfection. These instructions apply to RGP lens wearers without adjustments for specific systemic patient characteristics.

Handling and Procedural Constraints

The integrity of the solution is maintained by two key constraints. The solution must never be re-used or “topped off” in the storage case. Furthermore, it is specified that the entire contents of the bottle must be discarded 90 days after the bottle is first opened, regardless of the volume remaining. This duration constraint is based on product stability and quality maintenance over time.

Research evidence / Overview of Studies for Boston Simplus Multi-Action Solution

---

Evidence for Prophylactic Microbial Control and Disinfection Studies

Research for this solution was evaluated in laboratory studies designed to examine compliance with regulatory standards for Rigid Gas Permeable (RGP) lenses. These studies, often required for regulatory approval, included Stand-Alone Disinfection Tests that explored the solution's properties. The research examined the solution's characteristics, including its ability to achieve a logarithmic reduction, or "log-kill," of challenge microorganisms like Pseudomonas aeruginosa and Candida albicans when exposed over specific time intervals.

Studies reported measurements of antimicrobial activity that were used to explore the characteristics required by international regulatory standards for contact lens solution disinfection. The evidence is derived almost entirely from in-vitro models; no clinical trials were identified that directly link these lab results to patient outcomes related to microbial organisms in the long term. Long-term effects are not fully established and the highly controlled conditions of the laboratory research do not fully model all variables present in real-world use.

---

Evidence for Lens Cleaning and Deposit Removal

Studies explored the solution's role in managing surface contaminants on RGP lenses. This research involved in-vitro comparative cleaning models that explored the management of protein and lipid deposits on the lens surface. Additionally, post-clinical analyses were conducted on RGP lenses that had been worn by patients using the solution in clinical settings.

In-vitro studies described measurements of deposit removal characteristics against standardized levels of protein and lipids compared to control models. Analyses of lenses used in clinical studies reported on the visual appearance and cleanliness of the RGP lenses after use. Research relies primarily on laboratory-based performance models used for product submission, and evidence is limited regarding clinical data that directly measures whether characteristics related to deposit removal translate into quantifiable changes in patient visual function over a long period.

---

Evidence for Subjective Comfort and Handling Regimen

Randomized Controlled Trials (RCTs) and Comparative Clinical Studies were evaluated in studies examining patient-reported experiences of using the solution. The research was observed in adult RGP lens wearers and measured subjective scores related to daytime comfort and the ease of care and handling of their lenses, particularly when compared to conventional multi-step solutions.

Some comparative trials reported measurements of patient preference for the ease of the care regimen (cleaning, rinsing, storing) compared to conventional multi-step solutions. The sample sizes were modest in the published clinical trials, which means that results apply only to the populations studied. Furthermore, findings were mixed related to subjective outcomes like comfort and vision, sometimes lacking statistical distinction when compared to the control solution.

Common questions about Boston Simplus Multi-Action Solution (FAQ)

---

Q: Does Boston Simplus contain any preservatives?

A: Yes, official product documents indicate the solution contains Chlorhexidine gluconate and Polyaminopropyl biguanide. These ingredients function as the active agents, and official composition documents describe them as preservatives.

---

Q: What kind of studies were performed before the product was introduced?

A: According to regulatory submission summaries, the product was evaluated using several in-vitro laboratory studies. This research examined product stability, cleaning effectiveness, biological reactivity (toxicity), and microbiology studies to characterize disinfection performance before the solution was authorized.

---

Q: Are pregnant or breastfeeding people eligible to use this solution?

A: The official regulatory labeling is silent and provides no specific restrictions or recommendations for use during pregnancy or breastfeeding. Eligibility is primarily defined by the requirement to be an RGP lens wearer without a known allergy to any component.

---

Q: Is Boston Simplus considered a medical device or a drug by regulators?

A: This product is primarily regulated by the FDA through the 510(k) Premarket Notification process, which is the regulatory process for certain medical devices. Its function is for the care of the contact lens device, although it contains ingredients that act as ophthalmic biocides (disinfectants).

---

Q: What is the recommended temperature range for storing Boston Simplus?

A: Official labeling dictates that the solution should be stored at room temperature, specifically maintained between 15-30 C (59-86 F). Official instructions specify the need to avoid freezing and proximity to extreme heat or cold.

---

Q: How long can lenses stay in the case with Boston Simplus before needing a change?

A: The instructions state that lenses must be soaked for a minimum of four hours to achieve adequate chemical disinfection. The lenses are then typically stored submerged in the solution until they are ready to be worn next.

---

Q: Can Boston Simplus be purchased without a prescription?

A: Yes, the solution's official regulatory documentation confirms that it is classified with Over-the-Counter (OTC) Status, meaning it is legally available for purchase without a prescription.

---

Q: What are the official guidelines regarding expiration dates for an opened bottle?

A: There are two official time constraints: the bottle must be discarded 90 days after it is first opened, and the solution must always be used before the printed expiration date on the carton. The official guidance specifies adhering to whichever date is sooner.

---

Q: What should be done if an accidental small splash of the solution gets in the eye?

A: General guidance for accidental ocular exposure to this type of solution is to flush the eye immediately and thoroughly with water. If irritation continues, seeking professional assistance is indicated.

---

Q: What is the difference between soaking and rinsing with this solution?

A: The usage protocol defines two separate steps. Rinsing is a quick procedure intended to flush off loosened surface deposits. Soaking is the required minimum four-hour immersion phase that allows the chemical disinfection process to occur.

---

Q: Is there evidence that Boston Simplus is compatible with all rigid gas permeable (RGP) materials?

A: The solution's official documentation indicates its intended use for specific RGP materials: fluoro silicone acrylate and silicone acrylate contact lenses. Compatibility statements are limited to these materials mentioned in the regulatory clearance.

---

Q: Can I use tap water to rinse the lens case if I use Boston Simplus?

A: Official instructions and safety warnings specify that water should not be used for rinsing the lens case. The case must be cleaned, rinsed with fresh sterile solution, and air-dried to manage the risk of microbial contamination.

---

Q: Does using this product require a separate enzyme cleaner?

A: The product is designed to include a built-in protein remover and cleaner. Instructions derived from the regulatory clearance state that a separate daily cleaner is not required when using this multi-action solution.

---

Q: Why do official sources sometimes list different active ingredients for similar products?

A: Official regulatory documents, such as labeling or composition lists, can vary for similar products due to differences in geographical regulatory requirements. Product formulas may be modified to comply with the local health authority approvals and specific standards of different countries.

---

Q: Can exposure to heat affect the effectiveness of Boston Simplus?

A: Storage guidelines specifically require the solution to be kept away from extreme heat and cold. It is also mandated that the product must not be used in conjunction with heat (thermal) disinfection methods to maintain its chemical stability.

---

Q: Why is the packaging sometimes different between countries?

A: Packaging appearance and instructions are often adjusted to comply with the specific legal, safety, and language requirements of the local health authority in a given country or region that authorizes the product’s sale.

---

Q: What does the ingredient 'polyaminopropyl biguanide' do in the solution?

A: This substance is defined in official documents as one of the active ingredients, classified as an ophthalmic biocide (disinfectant). Its function is to disrupt the cell membranes of potential microbial contaminants to reduce the overall microbial load on the lens surface.

---

Q: What are the requirements for keeping the lens case clean when using this solution?

A: Official instructions require the interior of the lens case to be thoroughly cleaned, then rinsed with fresh sterile solution, and air-dried after each use. This procedure is required by the official instructions to help mitigate the risk of contamination.

How to Store and Dispose of Boston Simplus Multi-Action Solution

The storage and disposal instructions for the solution are defined by regulatory labeling to ensure product stability and safety. The product must be stored at room temperature, specifically maintained between 15-30 C (59-86 F), with a strict requirement to avoid freezing and proximity to extreme heat or cold.

For container integrity, the bottle must be kept tightly closed when not in use and stored out of the sight and reach of children.

Stability and Disposal

Condition	Requirement
In-Use Stability	Discard any remaining solution 90 days after opening the bottle.
Immediate Discard Rule	The solution used in the lens case must be discarded after each disinfection cycle; do not re-use.
Expiry	Use before the expiration date marked on the carton.

These official rules strictly govern the non-reuse of the solution and the time limit for use after the initial opening.